CHM.CN Waverunner Capital (CNQ) up 900% Mar 19 2026: volume spike merits caution

CHM.CN stock moved sharply in market hours after an intraday rise of 900.00%, pushing the share to C$0.05 on the CNQ exchange on 19 Mar 2026. Waverunner Capital Inc. (CHM.CN) traded above its 50-day average of C$0.04 and near the 200-day average of C$0.05, but reported volume was not published while the 30-day average volume sits at 28,908 shares. The price action followed a corporate rebrand to Waverunner Capital and renewed investor focus on its venture investments across healthcare and renewables. We examine what the move means for valuation, liquidity and near-term forecasts using Meyka AI market signals.

CHM.CN stock intraday move and trading context

Waverunner Capital Inc. (CHM.CN) recorded a one-day change from C$0.005 to C$0.05, a C$0.05 absolute gain and a 900.00% percentage move. Reported intraday volume was not available, but the stock’s average volume is 28,908 shares which makes any large block trade capable of causing outsized percentage swings.

The company’s year high is C$0.10 and year low is C$0.05, so today’s price sits at the lower end of the 52-week range by nominal value but shows strong short-term momentum relative to its 50-day average of C$0.04.

CHM.CN stock fundamentals and valuation metrics

At C$0.05 per share and 744,233,000 shares outstanding, market capitalization is roughly C$37,211,650.00. Trailing EPS is -0.01 and the reported PE is -5.00, reflecting negative earnings and limited operating scale.

Key ratios show material balance-sheet strain: current ratio 0.10, cash per share C$0.01, and book value per share -C$0.14, which indicates negative equity on a per-share basis. These metrics point to a speculative equity with weak fundamentals versus typical healthcare peers.

CHM.CN stock technical and liquidity signals

Short-term technicals show the price sitting above the 50-day average (C$0.04) and roughly in line with the 200-day average (C$0.05). Average trading liquidity is thin at 28,908 shares, so single trades can drive extreme percentage moves and create wide bid-ask spreads.

For high-volume mover strategies, the absence of confirmed intraday volume increases the execution risk; traders should expect volatility and potential price reversals when liquidity normalises.

Meyka AI rating and CHM.CN stock analysis

Meyka AI rates CHM.CN with a score out of 100: Score: 64.95 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

The grade reflects a mixed picture: a speculative valuation, negative EPS, small market cap C$37,211,650.00, but potential upside from portfolio holdings in renewables and biotech. These positives are balanced by low liquidity and negative book value.

CHM.CN stock catalysts, sector context and risks

Catalysts include portfolio exits, capital raises, or asset sales tied to their venture holdings; the rebrand from Chemistree Technology to Waverunner Capital in June 2024 increases investor attention. Healthcare sector performance in Canada is weak year-to-date at -4.28%, suggesting sector headwinds for small healthcare and specialty biotech names.

Primary risks are liquidity, continued negative EPS, potential dilution from financing, and volatile penny-stock dynamics. Given the company’s venture profile, news on specific portfolio investments will drive the most meaningful price updates.

CHM.CN stock outlook and scenario pricing

Base-case scenario: conservative recovery in portfolio valuations and a successful financing could support a move to a C$0.08 12-month price target. Bull-case scenario: asset sale or PIPE could lift shares toward the 52-week high of C$0.10.

Bear-case scenario: dilution or failed financings could push the price back toward C$0.01 or lower. Traders should size positions for high volatility and monitor issuance risk closely.

Final Thoughts

CHM.CN stock’s 900.00% intraday jump to C$0.05 on 19 Mar 2026 is a classic high-volume-mover signal in a low-liquidity microcap listed on CNQ in Canada. Fundamentals remain weak: negative EPS (-0.01), negative book value per share (-C$0.14), and a small market cap of C$37,211,650.00. Meyka AI’s grade is B (64.95), indicating a cautious HOLD stance given mixed drivers. Meyka AI’s forecast model projects a 12-month target of C$0.08, implying an upside of 60.00% from the current price of C$0.05; forecasts are model-based projections and not guarantees. For traders using a high-volume-movers strategy, the immediate opportunity is short-term momentum, but execution risks include thin liquidity and possible dilution. Monitor company announcements, financing notices and any confirmed volume prints before increasing exposure. Visit the Waverunner Capital website for corporate filings and the Meyka stock page for live updates: Meyka CHM.CN.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.